Absorbable iron-based alloy implanted medical device and manufacturing method thereof
Disclosed are an absorbable iron-based alloy implanted medical device ( 1 ) and preparation method thereof. The device ( 1 ) comprises an iron-based alloy base ( 11 ), a degradable polymer ( 13 ) arranged on the surface of the iron-based alloy base, and an alkaline protector ( 12 ) arranged on the surface of the iron-based alloy base. The alkaline protector ( 12 ) contains at least one alkaline substance capable of neutralizing the acidic substance produced by the polymer at the early stage after the device is implanted to delay the corrosion of the iron-based alloy base ( 1 ) in the early stage of implantation, hence the iron-based alloy base ( 12 ) would not substantially corrode or would corrode slowly, clinically satisfying the mechanical properties and requirements of the device ( 1 ) in the early stage of implantation; and in the meantime, after the neutralization and consumption of the alkaline protector ( 12 ) exposes the base ( 11 ), the base ( 11 ) can still accelerate the corrosion speed thereof in the acidic environment formed by the polymer ( 13 ), so as to clinically satisfy the requirement of the corrosion cycle of the device ( 1 ) at the same time.
1. An absorbable iron-based alloy stent, comprising an iron-based alloy substrate having a surface, an alkaline protector disposed on the surface of the iron-based alloy substrate and having a surface, and a degradable polymer disposed on the surface of the alkaline protector, and wherein the alkaline protector comprises at least one alkaline substance; and the alkaline substance is selected from the group consisting of sodium hydroxide, zinc hydroxide, zinc oxide, sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, sodium phosphate, sodium hydrogen phosphate, potassium phosphate, potassium hydrogen phosphate, sodium pyrophosphate, trisodium monohydrogen diphosphate, potassium pyrophosphate, tripotassium monohydrogen diphosphate, sodium polyphosphate, potassium polyphosphate, ammonium polyphosphate, sodium borate, potassium borate, calcium borate, sodium oxalate, potassium oxalate, calcium oxalate, trisodium citrate, sodium dihydrogen citrate, tripotassium citrate, potassium dihydrogen citrate, calcium citrate, calcium hydrogen citrate, sodium tartrate, potassium tartrate, calcium tartrate, ethylene diamine tetraacetic acid tetrasodium, ethylene diamine tetraacetic acid tetrapotassium, ethylene diamine tetraacetic acid calcium, sodium ethoxide, potassium ethoxide, calcium ethoxide, urea and hexamine; and
wherein the thickness of the alkaline protector is 6 μM, the thickness of the polymer is 8 μM, and the mass of the iron-based alloy substrate is 4.5-5 mg; or wherein the thickness of the alkaline protector is 20 μM, the thickness of the polymer is 12 μM, and the mass of the iron-based alloy substrate is 4.5-5 mg; or wherein the thickness of the alkaline protector is 20 μM, the thickness of the polymer is 8 μM, and the mass of the iron-based alloy substrate is 4.5-5 mg.
2. The absorbable iron-based alloy stent according to claim 1 , wherein the alkaline protector covers the entire surface of the iron-based alloy substrate, and the degradable polymer covers at least part of the surface of the alkaline protector.
3. The absorbable iron-based alloy implanted stent according to claim 1 , wherein the alkaline protector covers part of the surface of the iron-based alloy substrate, and the degradable polymer covers at least part of the surface of the alkaline protector and/or at least part of the surface of a region, which is not covered by the alkaline protector, in the iron-based alloy substrate.
4. The absorbable iron-based alloy stent according to claim 1 , wherein the alkaline protector comprises a weak acid and strong alkali salt which is selected from the group consisting of sodium pyrophosphate, trisodium monohydrogen diphosphate, potassium pyrophosphate, tripotassium monohydrogen diphosphate, sodium polyphosphate, potassium polyphosphate, ammonium polyphosphate, sodium borate, potassium borate, calcium borate, sodium oxalate, potassium oxalate, calcium oxalate, trisodium citrate, sodium dihydrogen citrate, tripotassium citrate, potassium dihydrogen citrate, calcium citrate, calcium hydrogen citrate, sodium tartrate, potassium tartrate, calcium tartrate, ethylene diamine tetraacetic acid tetrasodium and ethylene diamine tetraacetic acid tetrapotassium.
5. The absorbable iron-based alloy stent according to claim 1 , wherein the iron-based alloy substrate is pure iron or an iron-based alloy with a carbon content less than or equal to 2.11 wt. %.
6. The absorbable iron-based alloy stent according to claim 1 , wherein the degradable polymer is selected from degradable polyester and/or degradable polyanhydride; the degradable polyester is selected from the group consisting of polylactic acid, poly(lactic acid-glycolic acid), polycaprolactone, polyhydroxyalkanoate, polyacrylate, poly(ethylene succinate), poly(β-hydroxybutyrate) and polyethylene glycol adipate, or is selected from the group consisting of a physical blend of at least two of the polylactic acid, the polyglycolic acid, the poly(ethylene succinate), the poly(β-hydroxybutyrate), the polycaprolactone, the polyethylene glycol adipate, a polylactic acid-glycollic acid copolymer and a polyhydroxybutyrate-pentanoate copolymer, or is selected from the group consisting of copolymers formed by copolymerizing at least two of monomers forming the polylactic acid, the polyglycolic acid, the poly(ethylene succinate), the poly(β-hydroxybutyrate), the polycaprolactone, the polyethylene glycol adipate, the polylactic acid-glycollic acid copolymer and the polyhydroxybutyrate-pentanoate copolymer; and the degradable polyanhydride is selected from the group consisting of poly1,3-bis(p-carboxyphenoxy) propane-sebacic acid, poly(erucic acid dimer-sebacic acid) or poly(fumaric acid-sebacic acid), or the degradable polymer is a copolymer formed by copolymerizing at least two of monomers forming the degradable polyester and the degradable polyanhydride.
7. An absorbable iron-based alloy stent, comprising an iron-based alloy substrate having a surface, an alkaline protector disposed on the surface of the iron-based alloy substrate and having a surface, and a degradable polymer disposed on the surface of the alkaline protector, and wherein the alkaline protector comprises at least one alkaline substance; and the alkaline substance is selected from the group consisting of sodium hydroxide, zinc hydroxide, sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, sodium phosphate, sodium hydrogen phosphate, potassium phosphate, potassium hydrogen phosphate, sodium pyrophosphate, trisodium monohydrogen diphosphate, potassium pyrophosphate, tripotassium monohydrogen diphosphate, sodium polyphosphate, potassium polyphosphate, ammonium polyphosphate, sodium borate, potassium borate, calcium borate, sodium oxalate, potassium oxalate, calcium oxalate, trisodium citrate, sodium dihydrogen citrate, tripotassium citrate, potassium dihydrogen citrate, calcium citrate, calcium hydrogen citrate, sodium tartrate, potassium tartrate, calcium tartrate, ethylene diamine tetraacetic acid tetrasodium, ethylene diamine tetraacetic acid tetrapotassium, ethylene diamine tetraacetic acid calcium, sodium ethoxide, potassium ethoxide, calcium ethoxide, urea and hexamine;
wherein the alkaline protector further comprises a slow release assisted substance for prolonging the release time of the alkaline substance; the slow release assisted substance comprises a thickener; the thickener is mixed with the at least one alkaline substance to form a mixture; and the volume percentage of the alkaline substance in the mixture is greater than or equal to 20 percent but less than 100 percent; and
wherein the thickness of the alkaline protector is 6 μM, the thickness of the polymer is 8 μM, and the mass of the iron-based alloy substrate is 4.5-5 mg; or wherein the thickness of the alkaline protector is 20 μM, the thickness of the polymer is 12 μM, and the mass of the iron-based alloy substrate is 4.5-5 mg; or wherein the thickness of the alkaline protector is 20 μM, the thickness of the polymer is 8 μM, and the mass of the iron-based alloy substrate is 4.5-5 mg.
8. The absorbable iron-based alloy stent according to claim 7 , wherein the alkaline protector covers the entire surface of the iron-based alloy substrate, and the degradable polymer covers at least part of the surface of the alkaline protector.
9. The absorbable iron-based alloy implanted stent according to claim 7 , wherein the alkaline protector covers part of the surface of the iron-based alloy substrate, and the degradable polymer covers at least part of the surface of the alkaline protector and/or at least part of the surface of a region, which is not covered by the alkaline protector, in the iron-based alloy substrate.
10. The absorbable iron-based alloy stent according to claim 7 , wherein the alkaline protector comprises a weak acid and strong alkali salt which is selected from the group consisting of sodium pyrophosphate, trisodium monohydrogen diphosphate, potassium pyrophosphate, tripotassium monohydrogen diphosphate, sodium polyphosphate, potassium polyphosphate, ammonium polyphosphate, sodium borate, potassium borate, calcium borate, sodium oxalate, potassium oxalate, calcium oxalate, trisodium citrate, sodium dihydrogen citrate, tripotassium citrate, potassium dihydrogen citrate, calcium citrate, calcium hydrogen citrate, sodium tartrate, potassium tartrate, calcium tartrate, ethylene diamine tetraacetic acid tetrasodium and ethylene diamine tetraacetic acid tetrapotassium.
11. The absorbable iron-based alloy stent according to claim 7 , wherein the iron-based alloy substrate is pure iron or an iron-based alloy with a carbon content less than or equal to 2.11 wt. %.
12. The absorbable iron-based alloy stent according to claim 7 , wherein the degradable polymer is selected from degradable polyester and/or degradable polyanhydride; the degradable polyester is selected from the group consisting of polylactic acid, poly(lactic acid-glycolic acid), polycaprolactone, polyhydroxyalkanoate, polyacrylate, poly(ethylene succinate), poly(β-hydroxybutyrate) and polyethylene glycol adipate, or is selected from the group consisting of a physical blend of at least two of the polylactic acid, the polyglycolic acid, the poly(ethylene succinate), the poly(β-hydroxybutyrate), the polycaprolactone, the polyethylene glycol adipate, a polylactic acid-glycollic acid copolymer and a polyhydroxybutyrate-pentanoate copolymer, or is selected from the group consisting of copolymers formed by copolymerizing at least two of monomers forming the polylactic acid, the polyglycolic acid, the poly(ethylene succinate), the poly(β-hydroxybutyrate), the polycaprolactone, the polyethylene glycol adipate, the polylactic acid-glycollic acid copolymer and the polyhydroxybutyrate-pentanoate copolymer; and the degradable polyanhydride is selected from the group consisting of poly1,3-bis(p-carboxyphenoxy) propane-sebacic acid, poly(erucic acid dimer-sebacic acid) or poly(fumaric acid-sebacic acid), or the degradable polymer is a copolymer formed by copolymerizing at least two of monomers forming the degradable polyester and the degradable polyanhydride.
13. An absorbable iron-based alloy stent, comprising an iron-based alloy substrate having a surface, an alkaline protector disposed on the surface of the iron-based alloy substrate and having a surface, and a degradable polymer disposed on the surface of the alkaline protector, and wherein the alkaline protector comprises at least a weak acid and strong alkali salt; and the weak acid and strong alkali salt is selected from the group consisting of sodium pyrophosphate, trisodium monohydrogen diphosphate, potassium pyrophosphate, tripotassium monohydrogen diphosphate, sodium polyphosphate, potassium polyphosphate, ammonium polyphosphate, sodium borate, potassium borate, calcium borate, sodium oxalate, potassium oxalate, calcium oxalate, trisodium citrate, sodium dihydrogen citrate, tripotassium citrate, potassium dihydrogen citrate, calcium citrate, calcium hydrogen citrate, sodium tartrate, potassium tartrate, calcium tartrate, ethylene diamine tetraacetic acid tetrasodium and ethylene diamine tetraacetic acid tetrapotassium; and
wherein the thickness of the alkaline protector is 6 μM, the thickness of the polymer is 8 μM, and the mass of the iron-based alloy substrate is 4.5-5 mg; or wherein the thickness of the alkaline protector is 20 μM, the thickness of the polymer is 12 μM, and the mass of the iron-based alloy substrate is 4.5-5 mg; or wherein the thickness of the alkaline protector is 20 μM, the thickness of the polymer is 8 μM, and the mass of the iron-based alloy substrate is 4.5-5 mg.
14. The absorbable iron-based alloy stent according to claim 13 , wherein the alkaline protector further comprises a slow release assisted substance for prolonging the release time of the alkaline substance; the slow release assisted substance comprises a thickener; the thickener is mixed with the at least one alkaline substance to form a mixture; and the volume percentage of the alkaline substance in the mixture is greater than or equal to 20 percent but less than 100 percent.